Pfizer will manufacture remdesivir for Gilead at its facility in McPherson, Kan.
“From the beginning it was clear that no one company or innovation would be able to bring an end to the COVID-19 crisis,” Pfizer’s CEO, Albert Bourla, PhD, said in a news release. “Pfizer’s agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions.”
The agreement comes a couple days after 34 attorneys general wrote a letter urging federal health officials to boost the national supply of remdesivir.
More articles on pharmacy:
32 pharmacies ranked by customer satisfaction
Eli Lilly drug first in series to be studied as coronavirus treatment by NIH
An updated timeline on hydroxychloroquine, the controversial potential COVID-19 treatment
